Cargando…

Refractory Autoimmune Cytopenias Treated With Venetoclax

Detalles Bibliográficos
Autores principales:	Gordon, Max J., Maldonado, Edward, Danilov, Alexey V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746017/ https://www.ncbi.nlm.nih.gov/pubmed/31723832 http://dx.doi.org/10.1097/HS9.0000000000000202

Ejemplares similares

Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia
por: Crickx, Etienne, et al.
Publicado: (2021)

Two Cases of Autoimmune Neutropenia Complicated with Other Lineages of Autoimmune Cytopenia, Successfully Treated with Prednisolone
por: Adachi, Yoshiya, et al.
Publicado: (2020)

Primary Sjogren’s syndrome presenting as autoimmune cytopenia
por: Meena, Durga Shankar, et al.
Publicado: (2019)

Venetoclax for treating refractory autoimmune hemolytic anemia in chronic lymphocytic leukemia: report of two cases in Spain
por: Galindo-Navarro, Pablo, et al.
Publicado: (2023)

A Girl with Autoimmune Cytopenias, Nonmalignant Lymphadenopathy, and Recurrent Infections
por: Mattheij, Marjolein A. C., et al.
Publicado: (2012)

PB1846: MANAGEMENT OF PATIENTS TREATED WITH VENETOCLAX WITH HYPOMETHYLATING AGENTS: LONG-TERM INCIDENCE OF CYTOPENIAS AND INFECTIONS
por: Guardia-Torrelles, Ares, et al.
Publicado: (2023)

Membranous glomerulonephritis in a patient with myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia
por: Ko, Kwang Il, et al.
Publicado: (2013)

Autoimmune cytopenias in chronic lymphocytic leukemia
por: Haider, M. Shabih, et al.
Publicado: (2019)

Autoimmune Cytopenias In Common Variable Immunodeficiency
por: Podjasek, Jenna C., et al.
Publicado: (2012)

Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
por: D'Arena, Giovanni, et al.
Publicado: (2013)

Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
por: Laribi, Kamel, et al.
Publicado: (2022)

Targeted treatment of autoimmune cytopenias in primary immunodeficiencies
por: Pacillo, Lucia, et al.
Publicado: (2022)

Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant
por: McEwan, Ashley, et al.
Publicado: (2020)

Mycophenolate mofetil: Cytopenia: case report
Publicado: (2021)

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study
por: Montillo, M, et al.
Publicado: (2017)

Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax
por: Jehangir, Waqas, et al.
Publicado: (2020)

Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia
por: La Starza, Roberta, et al.
Publicado: (2019)

Autoimmune Cytopenias in Pediatric Hematopoietic Cell Transplant Patients
por: Neely, Jessica A., et al.
Publicado: (2019)

Autoimmune Cytopenias in Chronic Lymphocytic Leukemia, Facts and Myths
por: Tandra, Pavankumar, et al.
Publicado: (2013)

B-Cell Targeted Therapies in Autoimmune Cytopenias and Thrombosis
por: Matta, Bassem N., et al.
Publicado: (2013)

Leukoerythroblastosis with Cytopenia as an Initial Presentation of Lung Adenocarcinoma
por: Kotchetkov, Rouslan, et al.
Publicado: (2018)

Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia
por: Májek, Pavel, et al.
Publicado: (2011)

Alteration in Endoglin-Related Angiogenesis in Refractory Cytopenia with Multilineage Dysplasia
por: del Rey, Mónica, et al.
Publicado: (2013)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
por: Nguyen, Nina, et al.
Publicado: (2022)

Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias
por: Nikitin, Eugene, et al.
Publicado: (2023)

Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects
por: Fattizzo, Bruno, et al.
Publicado: (2020)

Autoimmune Cytopenias and Covid-19 Vaccination: Relapse and Suggested Treatment
por: Campos-Cabrera, Gregorio, et al.
Publicado: (2021)

Autoimmune Lymphoproliferative Syndrome in Children with Nonmalignant Organomegaly, Chronic Immune Cytopenia, and Newly Diagnosed Lymphoma
por: Kaya, Zühre, et al.
Publicado: (2021)

Venetoclax in Previously Treated Waldenström Macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2022)

Approaches to Managing Autoimmune Cytopenias in Novel Immunological Disorders with Genetic Underpinnings Like Autoimmune Lymphoproliferative Syndrome
por: Rao, V. Koneti
Publicado: (2015)

Cytopenia first – hepatitis second: an unusual sequence in aplastic anemia
por: Alashkar, Ferras, et al.
Publicado: (2017)

Antineoplastics: Cytopenia and COVID-19 pneumonia: 10 case reports
Publicado: (2021)

Acquired erythropoietic uroporphyria associated with clonal cytopenia of undetermined significance
por: Swanson, Leah A., et al.
Publicado: (2022)

Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V(2)) Therapy
por: Roche, Kyle C., et al.
Publicado: (2022)

Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations
por: Daido, Yusuke, et al.
Publicado: (2023)

Progressive Multifocal Leukoencephalopathy in B-CLL Successfully Treated With Venetoclax and Pembrolizumab
por: Olivieri, Jacopo, et al.
Publicado: (2022)

Secondary Hemophagocytic Lymphohistiocytosis and Autoimmune Cytopenias: Case Description and Review of the Literature
por: Fattizzo, Bruno, et al.
Publicado: (2021)

Primary Immunodeficiency in Children With Autoimmune Cytopenias: Retrospective 154-Patient Cohort
por: Westermann-Clark, Emma, et al.
Publicado: (2021)

Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax
por: Niswander, Lisa M., et al.
Publicado: (2023)

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
por: Huemer, Florian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8ln6tfqluhq8so7prj70dbdmlb